Truist Financial Downgrades Edwards Lifesciences(EW.US) to Hold Rating
Edwards Lifesciences Price Target Maintained With a $90.00/Share by Oppenheimer
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
UBS Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $75
UBS Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $75
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Edwards Lifesciences Is Maintained at Overweight by Wells Fargo
Edwards Lifesciences Analyst Ratings
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $80
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $80
Edwards Lifesciences: Hold Rating Amidst 2025 Earnings Uncertainty and Market Dynamics
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $82 From $91, Maintains Buy Rating
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
J.P. Morgan Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Announces Target Price $72
Balanced Outlook: Hold Rating on Edwards Lifesciences Amidst Market Uncertainties and Growth Potential
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $83
Deutsche Bank Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $85